Core Viewpoint - Nurix Therapeutics is set to present new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) at the European Hematology Association Congress, highlighting the company's focus on targeted protein degradation medicines for cancer treatment [1][5]. Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [5]. - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on innovative drug design [5]. - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline, supported by a fully AI-integrated discovery engine [5]. Clinical Trial Information - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule degrader of BTK, currently evaluated in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [4]. - The ongoing clinical trial can be accessed for additional information at clinicaltrials.gov (NCT05131022) [4]. Upcoming Presentations - The company will host a webcast conference call on June 12, 2025, to discuss the new data from the Phase 1 clinical trial, which will be presented at the EHA2025 [1][2]. - Presentations at EHA2025 include findings on the clinical activity and safety of bexobrutideg in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia, scheduled for June 13 and June 14, respectively [6].

Nurix Therapeutics (NRIX) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Rutideg, which we call bexdeg for short, being a degrader. We've got an important new suffix on there to indicate it's a degrader. So, I'll be calling it bexdeg n x five nine four eight. Speaker1 Okay. Bexdeg. Speaker0 Yeah, bexdeg. Speaker1 Yeah, awesome. So, maybe just to clarify, this EHA update will be focused on the phase 1a, more mature data, but not from the phase 1b expansion cohort for CLL. Speaker0 Right. It'll be on the ...

Nurix Therapeutics, Inc. (NRIX) shares soared 14.2% in the last trading session to close at $12.14. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.7% loss over the past four weeks.The stock rallied after the company announced that Sanofi has exercised its option to exclusively license Nurix’s STAT6 program, including the development candidate NX-3911, an oral, highly selective STAT6 degrader. Nurix is eligible to receive a lic ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and ...

Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com Kris Fortner Nurix Therapeutics Kfortner@nurixtx.com Contacts: Investors Kris Fortner Nurix Therapeutics, Inc. kfortner@nurixtx.com Elizabeth Wolffe, Ph.D. Wheelhouse Life Science Advisors lwolffe@wheelhouselsa.com Media SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein d ...

Summary of Nurix Therapeutics (NRIX) 2025 Conference Call Company Overview - Nurix Therapeutics specializes in targeted protein degradation, utilizing small molecules to degrade proteins via the ubiquitin proteasome system, rather than inhibiting them [3][4] - The company has developed a robust research platform called Dell AI, which includes large DNA encoded libraries for screening various protein targets [3] Key Programs and Developments - **Bexabrutinib**: - A BTK degrader moving into Phase II and Phase III studies in the second half of the year [4] - Target indications include Chronic Lymphocytic Leukemia (CLL) and Waldenstrom's macroglobulinemia [6] - Reported an 80% overall response rate (ORR) in heavily pretreated CLL patients [8] - Safety profile appears favorable with no new safety signals reported [10] - **Clinical Trials**: - Plans to initiate pivotal studies this year, focusing on a single-arm, single-agent accelerated approval strategy in third-line settings [15] - A randomized controlled study will also be initiated in the second-line plus setting [16] - Updates on trial designs and control arms expected mid-year [20] Competitive Landscape - BTK degradation is gaining enthusiasm in the investigator community as a new treatment modality, particularly for patients who have failed previous BTK inhibitors [12] - Nurix aims to differentiate its BTK degrader by addressing clinically relevant resistance mutations that arise from chronic treatment with BTK inhibitors [12] Strategic Partnerships - Collaborations with Gilead, Sanofi, and Pfizer are progressing well, with Gilead's IRAK4 program moving into clinical studies [30] - Sanofi is expected to advance the STAT6 development candidate towards IND status within approximately 12 months [30] Pipeline Expansion - Nurix is exploring indications beyond oncology, particularly in autoimmune diseases, with plans to initiate studies in autoimmune hemolytic anemia [27] - The company is cautious about funding these additional programs due to capital market challenges [28] Additional Assets - **NX-2127**: An oral BTK degrader showing promising results in aggressive malignancies, with rapid and long-lasting complete responses reported [38] - **Preclinical Programs**: Nurix is open to additional collaborations and has a pan-mutant BRAF degrader that addresses various mutations and resistance mechanisms [45] Financial Position - Nurix maintains a strong cash position and runway to advance its programs, with revenue contributions from collaborations helping to offset expenses [4] Conclusion - Nurix Therapeutics is at a pivotal point in its development, transitioning from a Phase I to a Phase II/III company with promising data and strategic partnerships that enhance its pipeline and market position [4][24]

SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 2:05 p.m. ET. The confere ...

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences. Da ...

Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, developmen ...

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour   BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase degraders demonstrate potential to address both enzymatic and scaffolding functions and promote tumor regression in brain and small cell lung cancer models  SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical- ...